Last reviewed · How we verify
BAT1706
BAT1706 is a bispecific antibody that simultaneously engages PD-1 on T cells and TGF-β in the tumor microenvironment to enhance anti-tumor immunity.
BAT1706 is a bispecific antibody that simultaneously engages PD-1 on T cells and TGF-β in the tumor microenvironment to enhance anti-tumor immunity. Used for Non-small cell lung cancer, Other solid tumors (in development).
At a glance
| Generic name | BAT1706 |
|---|---|
| Also known as | Bevacizumab Injection, BAT1706 |
| Sponsor | Bio-Thera Solutions |
| Drug class | Bispecific antibody; PD-1/TGF-β inhibitor |
| Target | PD-1 and TGF-β |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By blocking PD-1, BAT1706 relieves T cell exhaustion and restores anti-tumor immune responses. Simultaneously, it sequesters TGF-β, a potent immunosuppressive cytokine in the tumor microenvironment, further enhancing T cell activation and infiltration. This dual mechanism addresses two major immune checkpoints in cancer.
Approved indications
- Non-small cell lung cancer
- Other solid tumors (in development)
Common side effects
- Immune-related adverse events (irAEs)
- Fatigue
- Infusion reactions
Key clinical trials
- Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer (PHASE3)
- Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (PHASE2, PHASE3)
- Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer (PHASE3)
- Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer (PHASE3)
- A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer (PHASE2)
- Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study (PHASE3)
- Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies (PHASE3)
- Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BAT1706 CI brief — competitive landscape report
- BAT1706 updates RSS · CI watch RSS
- Bio-Thera Solutions portfolio CI